These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 16804113

  • 1. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.
    Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA, Wagner JE.
    Blood; 2006 Oct 15; 108(8):2874-80. PubMed ID: 16804113
    [Abstract] [Full Text] [Related]

  • 2. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
    Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG.
    Biol Blood Marrow Transplant; 2010 Feb 15; 16(2):287-91. PubMed ID: 19835968
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep 15; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

  • 7. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
    Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.
    Clin Transplant; 2018 Jan 15; 32(1):. PubMed ID: 29114932
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.
    Biol Blood Marrow Transplant; 2011 Jun 15; 17(6):901-7. PubMed ID: 20950702
    [Abstract] [Full Text] [Related]

  • 10. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study.
    Dumas PY, Ruggeri A, Robin M, Crotta A, Abraham J, Forcade E, Bay JO, Michallet M, Bertrand Y, Socié G, Ionescu I, Gluckman E, Milpied N, Rocha V.
    Bone Marrow Transplant; 2013 Feb 15; 48(2):253-6. PubMed ID: 22773124
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
    Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT.
    Transpl Infect Dis; 2019 Oct 15; 21(5):e13145. PubMed ID: 31301099
    [Abstract] [Full Text] [Related]

  • 17. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
    Scand J Infect Dis; 2007 Oct 15; 39(3):235-44. PubMed ID: 17366054
    [Abstract] [Full Text] [Related]

  • 18. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Milpied N, Coste-Burel M, Imbert-Marcille BM, Mohty M.
    Leukemia; 2011 Jun 15; 25(6):932-8. PubMed ID: 21350556
    [Abstract] [Full Text] [Related]

  • 19. Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.
    Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, Mori T, Kanda Y, Kondo T, Shiratori S, Miyakoshi S, Ishiyama K, Ikegame K, Matsuhashi Y, Tanaka J, Ichinohe T, Atsuta Y, Ogata M, Suzuki R.
    Biol Blood Marrow Transplant; 2019 Jul 15; 25(7):1441-1449. PubMed ID: 30794929
    [Abstract] [Full Text] [Related]

  • 20. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
    Lu Y, Wu T, Cao XY, Wang JB, Sun Y, Zhao YL, DA WM, Ji SQ, Tong CR, Lu DP.
    Zhonghua Nei Ke Za Zhi; 2011 May 15; 50(5):383-7. PubMed ID: 21624219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.